Timing is Crucial, Upside Analysis: Research Reports on Alder, Sky Solar, CNinsure, Raytheon, and Actavis

NEW YORK, December 29, 2014 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Alder (NASDAQ: ALDR), Sky Solar (NASDAQ: SKYS), CNinsure (NASDAQ: CISG), Raytheon (NYSE: RTN), and Actavis (NYSE: ACT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

ALDR Research Report: ( http://get.analystsreview.com/pdf/?c=Alder&d=29-Dec-2014&s=ALDR ),

SKYS Research Report: ( http://get.analystsreview.com/pdf/?c=Sky%20Solar&d=29-Dec-2014&s=SKYS ),

CISG Research Report: ( http://get.analystsreview.com/pdf/?c=CNinsure&d=29-Dec-2014&s=CISG ),

RTN Research Report: ( http://get.analystsreview.com/pdf/?c=Raytheon&d=29-Dec-2014&s=RTN ),

ACTResearch Report: ( http://get.analystsreview.com/pdf/?c=Actavis&d=29-Dec-2014&s=ACT ).

============

--

Analyst Update: S-1 Statement, FDA Approvals, Contract Awards, Leadership Changes, and Geographical Expansions

Reviewed by: Rohit Tuli, CFA®  

The U.S. stock market prolonged its winning streak on Friday, ending the day in green, as positive sentiments continued to buoy the markets after the Christmas holiday. The Dow Jones Industrial Average (DJIA) gained for seven consecutive trading days and ended the session at 18,053.71, up 0.13%, while the S&P 500 moved up 0.33% to 2088.77. The Nasdaq Composite advanced 0.70% and closed at 4,806.86, its highest level since March 2000. The European markets will remain close till Monday. The Asian stocks were mostly higher, as investors played down a slew of Japanese economic reports on inflation, industrial output and the labor market.  The data showed that inflation in Japan was slowing, despite efforts of increasing it; however, the market reaction to the November figures was largely muted.

ADRs of clinical-stage bio-pharmaceutical Company, Alder Biopharmaceuticals Inc. (Alder) shot up almost 10% in Friday's trade to end at $28.21.  Recently, the Company filed an S-1 registration to issue fresh shares, less than a year after the Company priced its IPO in May 2014 at $10.0 a share. Read the financial commentary on Alder and recent developments affecting the Company in our research report.

The ADRs of Sky Solar Holdings, Ltd. (Sky Solar) rallied 8.43% to end the trading session at $11.96. Recently, the Company reshuffled its executive team and announced its foray into the Chinese Solar Market. Read more about the Company's proposed entry into the Chinese market and the changes made to the senior level leadership team in our research report.

ADSs of CNinsure Inc. (CNinsure) - an insurance intermediary company operating in China, gained 8.90% to end at $6.85, amidst high trading volumes. On December 17, 2014, CNinsure announced that it has completed the previous announced share of its sale of ordinary shares to employees. A further detailed analysis of the share sale is presented in our research report. Click to know more.

Raytheon Company (Raytheon) awarded $491 million contract for Advanced Medium Range Air to Air Missile (AMRAAM). The contract comes close on the heels of a $2.4 billion contract to supply 10 Patriot missile defense systems to Qatar, which is beefing up its defenses to counter a growing perceived threat from Iran. Read more about the latest orders fetched by the U.S. weapons manufacturer - Raytheon, and more in our latest research report.

Actavis PLC (Actavis) is said to be interested in Spanish drug-maker Almirall SA, among a host of several other possible takeover targets, to expand its European footprints. U.S. FDA approved the New Drug Application for Actavis' Alzheimer's drug, even though it rejected its hypertension treatment drug. Read more about the potential bid and the latest regulatory developments affecting the Company in our research report on Actavis.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED